BACKGROUND: A number of genetic loci are associated with risk for Parkinson's disease (PD) based on genome-wide association studies; however, the relationship between genetic variants and nigrostriatal degeneration, which is the structural correlate of parkinsonism, has not been reported. OBJECTIVES: We quantified nigrostriatal dopaminergic integrity with image analysis of putaminal tyrosine hydroxylase immunoreactivity in 492 brains with Lewy body disease and used this pathologic endophenotype to explore possible association with PD genetic variants. METHODS: The study cases had Lewy-related pathology and variable degrees of nigrostriatal degeneration. They were assigned to one of the following clinical subgroups according to their predominant clinical syndrome: parkinsonism-predominant, parkinsonism+dementia, and dementia-predominant. In addition to putaminal tyrosine hydroxylase immunoreactivity, semiquantitative scoring was used to assess substantia nigra neuronal loss. A total of 29 PD genetic risk variants were genotyped on each case. RESULTS: When compared with controls, tyrosine hydroxylase immunoreactivity was reduced in Lewy body cases in the dorsolateral (79%) and ventromedial (57%) putamen. The dorsolateral region was better preserved in dementia-predominant cases than in cases with parkinsonism. Dorsolateral putaminal tyrosine hydroxylase immunoreactivity correlated with neuronal loss in the ventrolateral substantia nigra. Genetic analyses showed no significant association of PD risk variants with putaminal tyrosine hydroxylase immunoreactivity. CONCLUSIONS: The results confirm regional differences in putaminal dopaminergic degeneration and vulnerability of nigrostriatal pathway in Lewy body disorders with parkinsonism. The lack of association with PD genetic risk variants suggests that they may not be associated with quantitative endophenotypes of nigrostriatal degeneration, but more likely related to the risk of disease per se.
BACKGROUND: A number of genetic loci are associated with risk for Parkinson's disease (PD) based on genome-wide association studies; however, the relationship between genetic variants and nigrostriatal degeneration, which is the structural correlate of parkinsonism, has not been reported. OBJECTIVES: We quantified nigrostriatal dopaminergic integrity with image analysis of putaminal tyrosine hydroxylase immunoreactivity in 492 brains with Lewy body disease and used this pathologic endophenotype to explore possible association with PD genetic variants. METHODS: The study cases had Lewy-related pathology and variable degrees of nigrostriatal degeneration. They were assigned to one of the following clinical subgroups according to their predominant clinical syndrome: parkinsonism-predominant, parkinsonism+dementia, and dementia-predominant. In addition to putaminal tyrosine hydroxylase immunoreactivity, semiquantitative scoring was used to assess substantia nigra neuronal loss. A total of 29 PD genetic risk variants were genotyped on each case. RESULTS: When compared with controls, tyrosine hydroxylase immunoreactivity was reduced in Lewy body cases in the dorsolateral (79%) and ventromedial (57%) putamen. The dorsolateral region was better preserved in dementia-predominant cases than in cases with parkinsonism. Dorsolateral putaminal tyrosine hydroxylase immunoreactivity correlated with neuronal loss in the ventrolateral substantia nigra. Genetic analyses showed no significant association of PD risk variants with putaminal tyrosine hydroxylase immunoreactivity. CONCLUSIONS: The results confirm regional differences in putaminal dopaminergic degeneration and vulnerability of nigrostriatal pathway in Lewy body disorders with parkinsonism. The lack of association with PD genetic risk variants suggests that they may not be associated with quantitative endophenotypes of nigrostriatal degeneration, but more likely related to the risk of disease per se.
Authors: Sonja W Scholz; Tim Mhyre; Habtom Ressom; Salim Shah; Howard J Federoff Journal: Cold Spring Harb Perspect Med Date: 2012-07 Impact factor: 6.915
Authors: Anthony DelleDonne; Kevin J Klos; Hiroshige Fujishiro; Zeshan Ahmed; Joseph E Parisi; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Zbigniew K Wszolek; Ryan J Uitti; J Eric Ahlskog; Dennis W Dickson Journal: Arch Neurol Date: 2008-08
Authors: Albert A Davis; Kristin M Andruska; Bruno A Benitez; Brad A Racette; Joel S Perlmutter; Carlos Cruchaga Journal: Neurobiol Aging Date: 2015-09-30 Impact factor: 4.673
Authors: Dennis W Dickson; Hiroshige Fujishiro; Anthony DelleDonne; Joshua Menke; Zeshan Ahmed; Kevin J Klos; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Joseph E Parisi; J Eric Ahlskog Journal: Acta Neuropathol Date: 2008-02-09 Impact factor: 17.088
Authors: Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton Journal: Nat Genet Date: 2014-07-27 Impact factor: 38.330
Authors: Valentina Escott-Price; Mike A Nalls; Huw R Morris; Steven Lubbe; Alexis Brice; Thomas Gasser; Peter Heutink; Nicholas W Wood; John Hardy; Andrew B Singleton; Nigel M Williams Journal: Ann Neurol Date: 2015-03-13 Impact factor: 10.422
Authors: Marie Y Davis; Catherine O Johnson; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Zbigniew K Wszolek; Owen A Ross; Dennis W Dickson; David Eidelberg; Paul J Mattis; Martin Niethammer; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Megan Smith; Ignacio F Mata; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian Journal: JAMA Neurol Date: 2016-10-01 Impact factor: 18.302
Authors: Michael G Heckman; Koji Kasanuki; Rebecca R Brennan; Catherine Labbé; Emily R Vargas; Alexandra I Soto; Melissa E Murray; Shunsuke Koga; Dennis W Dickson; Owen A Ross Journal: Mov Disord Date: 2019-06-24 Impact factor: 10.338
Authors: Melinda C Power; Elizabeth Mormino; Anja Soldan; Bryan D James; Lei Yu; Nicole M Armstrong; Katherine J Bangen; Lisa Delano-Wood; Melissa Lamar; Yen Ying Lim; Kelly Nudelman; Laura Zahodne; Alden L Gross; Dan Mungas; Keith F Widaman; Julie Schneider Journal: Ann Neurol Date: 2018-06-26 Impact factor: 10.422
Authors: Rebecca R Valentino; Chloe Ramnarine; Michael G Heckman; Patrick W Johnson; Alexandra I Soto-Beasley; Ronald L Walton; Shunsuke Koga; Koji Kasanuki; Melissa E Murray; Ryan J Uitti; Julie A Fields; Hugo Botha; Vijay K Ramanan; Kejal Kantarci; Val J Lowe; Clifford R Jack; Nilufer Ertekin-Taner; Rodolfo Savica; Jonathan Graff-Radford; Ronald C Petersen; Joseph E Parisi; R Ross Reichard; Neill R Graff-Radford; Tanis J Ferman; Bradley F Boeve; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross Journal: Acta Neuropathol Commun Date: 2022-07-14 Impact factor: 7.578
Authors: Nobutaka Sakae; Keith A Josephs; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Jay van Gerpen; Neil R Graff-Radford; Dennis W Dickson Journal: Alzheimers Dement Date: 2019-08-06 Impact factor: 16.655
Authors: Nobutaka Sakae; Keith A Josephs; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Neil R Graff-Radford; Dennis W Dickson Journal: Mov Disord Date: 2019-08-21 Impact factor: 10.338